Boston Sci Makes Its Play In Transcatheter Valves With Sadra Acquisition
This article was originally published in The Gray Sheet
Executive SummaryBoston Scientific is entering the transcatheter aortic heart valve race in earnest with its deal, announced Nov. 19, to purchase the remainder of start-up firm Sadra Medical for up to $450 million.
You may also be interested in...
More patent litigation is emerging in the transcatheter aortic valve replacement space with two recent lawsuits alleging that Edwards Lifesciences' Sapien 3 TAVR device and delivery systems violated a total of nine patents held by Boston Scientific.
Data and trial updates in cardiology, oncology and more.
Potential growth drivers identified by the firm during its April 19 first-quarter earnings call include the Ingenio family of pacemakers and BSX-manufactured Promus Element everolimus-eluting stent system.